Global Peptide CDMO (Pharmaceutical) Market

Report ID : 1202 | Published : 2022-03-25 | Pages: 146 | Format:

The global Peptide CDMO (Pharmaceutical) market size was accounted at USD 2028.60 Mn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2022 to 2030. The Global peptide CDMO (Pharmaceutical) market size was valued at US$ 2028.60 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2022 to 2030. Peptides are bioactive molecules that bind to specific cell surface receptors, such as G protein-coupled receptors (GPCRs) or ion channels, where they trigger intracellular effects. Peptides have characteristics like safety, high specificity, and targeted drug delivery which are expected to create the future potential of expanding peptide therapeutics business. Increasing clinical demand for peptides favours the business of CDMOs.

Major driving factors of the peptide CDMO (pharmaceutical) market are the growing clinical applications of peptides, advancements in medical technologies, surging investments by pharma companies in peptides to develop drug therapies, increasing cases of chronic diseases, and a growing number of health-conscious people. Several drug developing industries outsource their peptide production operations to CDMOs (contract research, development and manufacturing organization) to achieve better operational efficiency and flexibility, which is projected to propel the growth of the peptide CDMO (pharmaceutical) market in the coming years. However, the high cost of outsourced services and the need for specialized expertise for peptide production may restrict the market growth during the projected period.

The peptide CDMO (pharmaceutical) market is segmented based on the scale of operation, method used, applications, synthesis types, and region. The scale of operation segment comprises preclinical/clinical and commercial. By method used, the market is classified into chemical synthesis method and non-chemical synthesis method. The market is segmented into peptide supplements, peptide vaccines, peptides as radio-theranostic agents, cell-penetrating peptides (CPPs), affinity ligands, and protein mimics based on applications. The market is divided into LPPS (Liquid-phase Peptide Synthesis), SPPS (Solid-phase Peptide Synthesis), and Mixed Phase by synthesis types. SPPS segment is expected to dominate this market over the forecast period. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, & the Middle East and Africa.

Asia-Pacific is expected to witness the fastest growth in the next few years due to the rising applications of peptides, increasing government initiatives in the R&D of peptide-based products & treatments, and the high prevalence of chronic diseases. Some of the key players operating in the peptide CDMO (pharmaceutical) market are AmbioPharm, Auspep, Bachem, BCN Peptide, CPC Scientific, CBL- Chemical and Biopharmaceutical Laboratories, Creative Peptides, Chinese Peptide, CSBio, Corden Pharma, PolyPeptide, Hybio Pharmaceutical, Peptide Institute, Pepscan, Almac, Vivitide, CreoSalus Inc, ScinoPharm, Senn Chemicals, Wuxi AppTec, Olon, Belyntic, Ferring Pharma, Numaferm, Hybio Pharmaceutical, Provepharm Life Solutions, Enzene Biosciences, Ardena Holding, Stelis Biopharma, Piramal Pharma, Space Peptides Pharmaceutical, and others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Peptide CDMO (Pharmaceutical) Market Snapshot

Chapter 4. Global Peptide CDMO (Pharmaceutical) Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis

5.1. By Scale of Operation, & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Scale of Operation:

5.2.1. Preclinical / Clinical

5.2.2. Commercial

Chapter 6. Market Segmentation 2: By Applications Estimates & Trend Analysis

6.1. By Method Used & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Method Used:

6.2.1. Chemical Synthesis Method

6.2.2. Non-Chemical Synthesis Method

Chapter 7. Market Segmentation 3: By Synthesis Types Estimates & Trend Analysis

7.1. By Applications & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Applications:

7.2.1. Peptide Supplements

7.2.2. Peptide Vaccines

7.2.3. Peptides as Radio-Theranostic Agents

7.2.4. Cell Penetrating Peptides (CPPs)

7.2.5. Affinity Ligands

7.2.6. Protein Mimics

Chapter 8. Market Segmentation 4: By Synthesis Types Estimates & Trend Analysis

8.1. By Synthesis Types & Market Share, 2020& 2030

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Synthesis Types

8.2.1. LPPS

8.2.2. SPPS

8.2.3. Mixed Phase

Chapter 9. Peptide CDMO (Pharmaceutical) Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts By Scale of Operation, 2019-2030

9.1.2. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts By Method Used, 2019-2030

9.1.3. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Applications, 2019-2030

9.1.4. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Synthesis Types, 2019-2030

9.1.5. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2030

9.2. Europe

9.2.1. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, 2019-2030

9.2.2. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, 2019-2030

9.2.3. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, 2019-2030

9.2.4. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2019-2030

9.2.5. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by country, 2019-2030

9.3. Asia Pacific

9.3.1. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, 2019-2030

9.3.2. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, 2019-2030

9.3.3. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, 2019-2030

9.3.4. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2019-2030

9.3.5. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by country, 2019-2030

9.4. Latin America

9.4.1. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

9.4.2. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, (US$ Million) 2019-2030

9.4.3. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, (US$ Million) 2019-2030

9.4.4. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Synthesis Types, 2019-2030

9.4.5. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by Country, 2019-2030

9.5. Middle East & Africa

9.5.1. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

9.5.2. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, (US$ Million) 2019-2030

9.5.3. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, (US$ Million) 2019-2030

9.5.4. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2019-2030

9.5.5. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by Country, 2019-2030

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

 

10.2.1. AmbioPharm

10.2.2. Auspep

10.2.3. Bachem

10.2.4. BCN Peptide

10.2.5. CPC Scientific

10.2.6. CBL- Chemical and Biopharmaceutical Laboratories

10.2.7. Creative Peptides

10.2.8. Chinese Peptide

10.2.9. CSBio

10.2.10. Corden Pharma

10.2.11. PolyPeptide

10.2.12. Hybio Pharmaceutical

10.2.13. Peptide Institute

10.2.14. Pepscan

10.2.15. Almac

10.2.16. vivitide

10.2.17. CreoSalus Inc

10.2.18. ScinoPharm

10.2.19. Senn Chemicals

10.2.20. Wuxi AppTec

10.2.21. Olon

10.2.22. Belyntic

10.2.23. Ferring Pharma

10.2.24. Numaferm

10.2.25. Hybio Pharmaceutical

10.2.26. Provepharm life solutions

10.2.27. Enzene Biosciences

10.2.28. Ardena Holding

10.2.29. Stelis Biopharma

10.2.30. Piramal Pharma

10.2.31. Space Peptides Pharmaceutical

10.2.32. Other Prominent Players

Global Peptide CDMO (Pharmaceutical) Market, by Scale of Operation, 2022-2030 (Value US$ Mn)

  • Preclinical / Clinical
  • Commercial

Global Peptide CDMO (Pharmaceutical) Market, by Method Used, 2022-2030 (Value US$ Mn)

  • Chemical Synthesis Method
  • Non-Chemical Synthesis Method

Global Peptide CDMO (Pharmaceutical) Market, by By Applications, 2022-2030 (Value US$ Mn)

  • Peptide Supplements
  • Peptide Vaccines
  • Peptides as Radio-Theranostic Agents
  • Cell Penetrating Peptides (CPPs)
  • Affinity Ligands
  • Protein Mimics

Global Peptide CDMO (Pharmaceutical) Market, by Synthesis Types, 2022-2030 (Value US$ Mn)

  • LPPS
  • SPPS
  • Mixed Phase

Global Peptide CDMO (Pharmaceutical) Market, by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa 

Company Profiles

  • AmbioPharm
  • Auspep
  • Bachem
  • BCN Peptide
  • CPC Scientific
  • CBL- Chemical and Biopharmaceutical Laboratories
  • Creative Peptides
  • Chinese Peptide
  • CSBio
  • Corden Pharma
  • PolyPeptide
  • Hybio Pharmaceutical
  • Peptide Institute
  • Pepscan
  • Almac
  • vivitide
  • CreoSalus Inc
  • ScinoPharm
  • Senn Chemicals
  • Wuxi AppTec
  • Olon
  • Belyntic
  • Ferring Pharma
  • Numaferm
  • Hybio Pharmaceutical
  • Provepharm life solutions
  • Enzene Biosciences
  • Ardena Holding 
  • Stelis Biopharma
  • Piramal Pharma
  • Space Peptides Pharmaceutical

Other Prominent Players

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Global Peptide CDMO (Pharmaceutical) Market?

Peptide CDMO (Pharmaceutical) Market worth US$ 4.32 Billion by 2030

CAGR of 9.0% during the forecast period of 2022-2030.

Our Clients